Brian M. Hahn

CIK 1589711 · SVP Finance, CFO · last filed 2024-06-20

Brian M. Hahn is a SVP Finance, CFO who has filed 18 SEC Form 4 insider transactions across 1 company since 2014. The most recent filing shows the insider bought $4.3K of GLYC on Jun 20, 2024. Across all open-market trades the lifetime net is −$333.8K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

18

Lifetime Open-Market Net

-$333.8K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRESCENT BIOPHARMA, INC. (GLYC) Delisted SVP Finance, CFO 70,643 $15.70 $1.11M -$333.8K 18 2024-06-20

Recent Filings

18 filings
Form 4 transactions across all companies, newest first.
Filed Symbol Action Net Shares Net $ Link
2024-06-20 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +17,500 $4.3K EDGAR
2024-01-17 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) $0 EDGAR
2023-05-18 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Sell (S) −3,700 -$7.2K EDGAR
2023-01-20 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) $0 EDGAR
2022-11-14 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Buy (P) +20,000 $21.2K EDGAR
2022-03-10 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Sell (S) −2,917 -$3.2K EDGAR
2022-01-25 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) $0 EDGAR
2021-01-22 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) +34,500 $0 EDGAR
2020-12-17 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Exer (M) +5,260 $5.9K EDGAR
2020-01-24 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) $0 EDGAR
Showing 110 of 18
Page 1 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.